AU2018300985B2 - Compounds for the reducing lipotoxic damage - Google Patents
Compounds for the reducing lipotoxic damage Download PDFInfo
- Publication number
- AU2018300985B2 AU2018300985B2 AU2018300985A AU2018300985A AU2018300985B2 AU 2018300985 B2 AU2018300985 B2 AU 2018300985B2 AU 2018300985 A AU2018300985 A AU 2018300985A AU 2018300985 A AU2018300985 A AU 2018300985A AU 2018300985 B2 AU2018300985 B2 AU 2018300985B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- subject
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
- C07D305/12—Beta-lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024278291A AU2024278291A1 (en) | 2017-07-12 | 2024-12-11 | Compounds for the reducing lipotoxic damage |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531454P | 2017-07-12 | 2017-07-12 | |
| US62/531,454 | 2017-07-12 | ||
| PCT/US2018/041796 WO2019014434A1 (en) | 2017-07-12 | 2018-07-12 | COMPOUNDS FOR REDUCING LIPOTOXIC LESIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024278291A Division AU2024278291A1 (en) | 2017-07-12 | 2024-12-11 | Compounds for the reducing lipotoxic damage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018300985A1 AU2018300985A1 (en) | 2020-01-30 |
| AU2018300985B2 true AU2018300985B2 (en) | 2024-09-12 |
Family
ID=65002124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018300985A Active AU2018300985B2 (en) | 2017-07-12 | 2018-07-12 | Compounds for the reducing lipotoxic damage |
| AU2024278291A Pending AU2024278291A1 (en) | 2017-07-12 | 2024-12-11 | Compounds for the reducing lipotoxic damage |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024278291A Pending AU2024278291A1 (en) | 2017-07-12 | 2024-12-11 | Compounds for the reducing lipotoxic damage |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US11339126B2 (https=) |
| EP (2) | EP3651784B1 (https=) |
| JP (1) | JP7224331B2 (https=) |
| KR (1) | KR102679975B1 (https=) |
| CN (1) | CN111343999B (https=) |
| AU (2) | AU2018300985B2 (https=) |
| BR (1) | BR112020000635B1 (https=) |
| CA (1) | CA3069526A1 (https=) |
| DK (1) | DK4218753T3 (https=) |
| ES (1) | ES2934883T3 (https=) |
| IL (1) | IL271884B2 (https=) |
| PL (2) | PL4218753T3 (https=) |
| SG (1) | SG11202000239XA (https=) |
| WO (1) | WO2019014434A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000239XA (en) | 2017-07-12 | 2020-02-27 | Mayo Found Medical Education & Res | Compounds for the reducing lipotoxic damage |
| MX2023012532A (es) * | 2021-04-23 | 2023-11-29 | Panafina Inc | Metodos de sintetizacion de derivados de lipstatina. |
| CN114560887B (zh) * | 2022-02-15 | 2024-01-26 | 安徽美致诚药业有限公司 | 一种制备奥利司他的中间体的制备方法 |
| AU2023243617A1 (en) * | 2022-03-31 | 2024-10-03 | Mayo Foundation For Medical Education And Research | Methods and materials for treating pancreatic diseases and disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA859575B (en) * | 1984-12-21 | 1986-08-27 | Hoffmann La Roche | Oxetanones |
| CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| IL97148A (en) * | 1990-02-26 | 1996-11-14 | Hoffmann La Roche | Oxetanones a process for their manufacture and pharmaceutical compositions containing them |
| FR2754827B1 (fr) | 1996-10-17 | 1998-12-24 | Biocem | Lipases pancreatiques et/ou colipases recombinantes et polypeptides dervies produits par les plantes, leurs procedes d'obtention et leurs utilisations |
| FR2758143B1 (fr) | 1997-01-07 | 1999-02-19 | Laphal Laboratoire De Pharmaco | Inhibiteurs specifiques de la lipase pancreatique et leurs applications |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US20040018197A1 (en) | 2002-04-26 | 2004-01-29 | Promega Corporation | Treatment for weight loss |
| DE102004009076A1 (de) | 2004-02-23 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP1803714A1 (en) | 2005-12-27 | 2007-07-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Process for preparing crystalline forms of orlistat |
| WO2009059046A1 (en) | 2007-10-31 | 2009-05-07 | Burnham Institute For Medical Research | Beta-lactone compounds |
| US9023887B2 (en) | 2011-04-15 | 2015-05-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | Lipase inhibitors for the treatment of pancreatitis and organ failure |
| US20150099800A1 (en) | 2012-05-24 | 2015-04-09 | Northeastern University | Novel lipase inhibitors, reporter substrates and uses thereof |
| CN106470804B (zh) | 2014-06-30 | 2019-09-10 | 工机控股株式会社 | 电动工具 |
| WO2016102541A1 (en) | 2014-12-22 | 2016-06-30 | Université Libre de Bruxelles | Composition comprising vancomycin and orlistat |
| US20180319894A1 (en) | 2015-11-03 | 2018-11-08 | Mayo Foundation For Medical Education And Research | Using colipase inhibitors to treat pancreatitis |
| SG11202000239XA (en) | 2017-07-12 | 2020-02-27 | Mayo Found Medical Education & Res | Compounds for the reducing lipotoxic damage |
-
2018
- 2018-07-12 SG SG11202000239XA patent/SG11202000239XA/en unknown
- 2018-07-12 EP EP18831486.8A patent/EP3651784B1/en active Active
- 2018-07-12 PL PL22197886.9T patent/PL4218753T3/pl unknown
- 2018-07-12 JP JP2020501125A patent/JP7224331B2/ja active Active
- 2018-07-12 PL PL18831486.8T patent/PL3651784T3/pl unknown
- 2018-07-12 EP EP22197886.9A patent/EP4218753B1/en active Active
- 2018-07-12 KR KR1020207003413A patent/KR102679975B1/ko active Active
- 2018-07-12 AU AU2018300985A patent/AU2018300985B2/en active Active
- 2018-07-12 ES ES18831486T patent/ES2934883T3/es active Active
- 2018-07-12 WO PCT/US2018/041796 patent/WO2019014434A1/en not_active Ceased
- 2018-07-12 CN CN201880057761.7A patent/CN111343999B/zh active Active
- 2018-07-12 US US16/629,842 patent/US11339126B2/en active Active
- 2018-07-12 DK DK22197886.9T patent/DK4218753T3/da active
- 2018-07-12 CA CA3069526A patent/CA3069526A1/en active Pending
- 2018-07-12 BR BR112020000635-1A patent/BR112020000635B1/pt active IP Right Grant
-
2020
- 2020-01-07 IL IL271884A patent/IL271884B2/en unknown
-
2022
- 2022-04-20 US US17/725,281 patent/US11623915B2/en active Active
-
2023
- 2023-03-03 US US18/178,062 patent/US11976040B2/en active Active
-
2024
- 2024-04-17 US US18/637,793 patent/US12325690B2/en active Active
- 2024-12-11 AU AU2024278291A patent/AU2024278291A1/en active Pending
-
2025
- 2025-05-14 US US19/207,836 patent/US20250340512A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11623915B2 (en) | Compounds for the reducing lipotoxic damage | |
| JP6989505B2 (ja) | Ｍａｌｔ１阻害剤およびその使用 | |
| JP7012289B2 (ja) | ベンゾイルグリシン誘導体およびその作製および使用の方法 | |
| HK40029799A (en) | Compounds for the reducing lipotoxic damage | |
| HK40029799B (en) | Compounds for the reducing lipotoxic damage | |
| RU2776343C2 (ru) | Соединения для снижения липотоксического повреждения | |
| WO2024020409A1 (en) | Therapeutic compounds, formulations, and use thereof | |
| EP4017844B1 (en) | Compounds and use thereof for the treatment of infectious diseases and cancer | |
| EP3368512A1 (en) | Indoline derivatives for treatment and/or prevention of fibrosis diseases | |
| US8680125B2 (en) | Fullerene therapies for inflammation | |
| US12583834B2 (en) | Method of treating bacterial infections and pharmaceutical composition for treating bacterial infections | |
| EP4065117A1 (en) | Isoquinoline derivatives for use in treating glut1 deficiency syndrome | |
| US11608320B2 (en) | Oxazolidinone hydroxamic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |